阿立哌唑与精神科住院、自伤或自杀风险的关系
基于英国CPRD等数据库的人群队列研究,将1643例换用或加用阿立哌唑者与1643例换用或加用其他抗精神病药者1:1倾向匹配。随访2692人年发生391例严重精神科治疗失败,阿立哌唑组精神科治疗失败(HR 0.87;95%CI 0.71-1.06)、精神科住院(HR 0.85;95%CI 0.69-1.06)、自伤或自杀(HR 0.96;95%CI 0.68-1.36)风险均未升高。
要点
- 既往用过抗精神病药者换用或加用阿立哌唑,未观察到精神科住院、自伤或自杀风险升高。
- 主要结局HR 0.87(95%CI 0.71-1.06),多项敏感性分析结果一致。
- 结果为观察性研究,作者提示需在大型观察性研究中重复验证。
核心结论
- 在既往已暴露于抗精神病药的患者中,起始阿立哌唑相比起始其他抗精神病药,未显示与精神科住院、自伤或自杀风险升高相关。
- 作者指出该发现需在大型观察性研究中重复验证。
研究设计与样本
- 研究为基于人群的队列研究,数据来自英国临床实践研究数据链(CPRD),并与医院统计库及国家统计局死亡数据库链接,时间范围为2005年1月1日至2015年3月31日。
- 在新使用抗精神病药的基础队列中,换用或加用阿立哌唑者(n=1643)按1:1倾向评分匹配至换用或加用其他抗精神病药者(n=1643)。
- 随访至精神科治疗失败、入组后365天、非自杀原因死亡、登记或数据库链接结束、或研究期结束(2016年3月31日)。
- 采用Cox比例风险回归模型估计风险比(HR)及95%CI,并在倾向评分匹配基础上调整年龄、入组前6个月精神科住院或自伤事件数、入组前不同抗精神病药数量及多重剥夺指数五分位。
主要发现
- 阿立哌唑组1643例中949例(57.8%)为女性,平均(SD)年龄42.1(16.8)岁;对照其他抗精神病药组1643例中871例(53.0%)为女性,平均(SD)年龄42.4(17.1)岁。
- 随访共2692人年,发生391例新发严重精神科治疗失败,粗发病率为14.52(95%CI 13.16-16.04)/100人年。
- 首次使用阿立哌唑与精神科治疗失败风险无关(HR 0.87;95%CI 0.71-1.06)。
- 首次使用阿立哌唑与精神科住院风险无关(HR 0.85;95%CI 0.69-1.06)。
- 首次使用阿立哌唑与自伤或自杀风险无关(HR 0.96;95%CI 0.68-1.36)。
关键数值与推荐
- 主要结局为严重精神科治疗失败,包括精神科住院、自伤或自杀。
- 阿立哌唑组与对照组的匹配方式为1:1倾向评分匹配,匹配后各1643例。
- 模型除倾向评分匹配外,还调整年龄、入组前6个月精神科住院或自伤事件数、入组前不同抗精神病药数量及多重剥夺指数五分位。
- 结果在多项敏感性分析中保持一致。
临床怎么用
- 对于既往已使用抗精神病药、需换药或加药的患者,阿立哌唑可作为不增加精神科住院、自伤或自杀风险的选项之一。
- 临床决策仍需结合个体既往用药、病情与监测条件,该观察性结果不构成因果关系证明。
局限性
- 研究为观察性设计,作者明确提示结果需在大型观察性研究中重复验证。
- 摘要未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Some reports have raised concerns regarding a potential psychiatric worsening associated with first-time use of aripiprazole in patients already treated with other antipsychotic medications. Whether aripiprazole use, particularly in the long term, increases the risk for serious psychiatric events is unclear. OBJECTIVE: To assess whether switching to or adding aripiprazole is associated with serious psychiatric treatment failure compared with switching to or adding another antipsychotic drug in patients previously exposed to antipsychotic medications. DESIGN, SETTING, AND PARTICIPANTS: This population-based cohort study was conducted from January 1, 2005, to March 31, 2015. Data were obtained from the United Kingdom Clinical Practice Research Datalink, one of the world's largest computerized databases linked to the Hospital Episodes Statistics repository and the Office for National Statistics (ONS) mortality database. Within a base cohort of new users of antipsychotic drugs, patients switching or adding aripiprazole (n = 1643) were propensity matched 1:1 to patients switching to or adding another antipsychotic medication (n = 1643). All patients were followed up until psychiatric treatment failure, for 365 days (1 year) after cohort entry, until death from any cause other than suicide, until end of registration or linkage with the databases, or end of the study period (March 31, 2016). MAIN OUTCOMES AND MEASURES: Cox proportional hazards regression models were used to estimate hazard ratios (HRs) and 95% CIs of serious events of psychiatric treatment failure (psychiatric hospitalizations, self-harm, or suicide) associated with switching to or adding aripiprazole compared with other antipsychotic drugs. In addition to propensity score matching, all models were adjusted for age, number of psychiatric hospitalizations or self-harm events in the 6 months before cohort entry, number of different antipsychotic drugs before cohort entry, and quintiles of the Index of Multiple Deprivation. RESULTS: The study cohort included 1643 patients (949 [57.8%] were women with a mean [SD] age of 42.1 [16.8] years) starting aripiprazole use; they were matched 1:1 to 1643 patients (871 [53.0%] were women with a mean [SD] age of 42.4 [17.1] years) starting use of another antipsychotic drug. During 2692 person-years of follow-up, 391 incident serious psychiatric treatment failures occurred, with a crude incidence rate of 14.52 (95% CI, 13.16-16.04) per 100 person-years. First-time use of aripiprazole was not associated with an increased rate of psychiatric treatment failure (HR, 0.87; 95% CI, 0.71-1.06), psychiatric hospitalizations (HR, 0.85; 95% CI, 0.69-1.06), or self-harm or suicide (HR, 0.96; 95% CI, 0.68-1.36) compared with starting use of another antipsychotic drug. Results were consistent across several sensitivity analyses. CONCLUSIONS AND RELEVANCE: Initiating aripiprazole use, compared with another antipsychotic medication, after a previous antipsychotic exposure did not appear to be associated with psychiatric hospitalization, self-harm, or suicide; these findings warrant replication in large observational studies.
引用
- Montastruc F, Nie R, Loo S, et al. Association of Aripiprazole With the Risk for Psychiatric Hospitalization, Self-harm, or Suicide. JAMA Psychiatry. 2019. PMID: 30698607. doi:10.1001/jamapsychiatry.2018.4149
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。